AFP and hepatocellular carcinoma: Because the modified AFP promoter, in conjunction with HREs, could induce a high level of gene expression by replication-incompetent Ads in a HCC-specific manner, we constructed a series of oncolytic Ads, incorporating these promoter variants, to effectively target AFP-positive HCCs.